Similarly, another mouse model of breast cancer showed that the therapeutic effect of doxorubicin depended on IFN-γ production by CD8+ T cells and that IL-17 and IL-1β induction was required to achieve a therapeutic effect [21]. This evidence concerns the gene IL17A and breast cancer.